Skin Cancer News
A 75% reduction in SCC risk was observed among patients in the fluorouracil arm vs the placebo-arm.
Baseline tumor size and PD-L1 status were independently associated with the likelihood of a complete response.
The drug combination was studied in patients with BRAFV600E/K mutations in the phase 3 COMBI-AD study, the results of which led to the FDA's Priority Review designation.
Previous studies have demonstrated that melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.
Four hundred and twenty-seven tanning salons were contacted; 32.7% of contacted salons were non-compliant with their respective state's regulations.
Dabrafenib plus trametinib is the first adjuvant therapy indicated specifically for melanoma with the BRAFV600 mutation.
Researchers evaluated data from 7629 patients with melanoma included in the North Carolina cancer registry to determine relevant variables associated with delayed surgery.
Researchers collected ctDNA samples from patients with varying cancer types to determine whether liquid biopsies may help to predict response to checkpoint inhibition.
Previous studies demonstrated that propranolol may inhibit angiogenesis and migration of cancer cells, leading to a delay in disease progression.
Investigators randomly assigned 870 patients with advanced melanoma who had undergone complete resection to receive trametinib and dabrafenib vs placebo for 1 year.
The randomized phase 3 CheckMate 238 trial evaluated the safety and efficacy of nivolumab vs ipilimumab in the resected stage III/IV melanoma setting.
CSCC has the second highest mortality rate among skin cancers after melanoma.
Binimetinib a BRAF inhibitor, improved objective response rate (ORR) and progression-free survival (PFS) among patients with BRAF-mutant melanoma.
After the second interim analysis, an external data monitoring committee recommended that pembrolizumab be made available to patients receiving ipilimumab whose disease had progressed despite treatment.
Researchers are evaluating whether 6MHP, a peptide vaccine, is safe and efficacious when combined with ipilimumab in patients with stage IIIB or higher melanoma.
Researchers enrolled 17,202 individuals, half of whom were cancer survivors and half of whom were healthy controls, to compare opioid prescription rates between the 2 groups.
Researchers reviewed findings from 13 case-control/cohort studies to determine any link between alcohol intake and non-melanoma skin cancer.
The FDA approved the indication expansion for ipilimumab based on evidence from 2 clinical trials evaluating its safety and efficacy in pediatric patients.
Patients with advanced melanoma may have good outcomes when treated with standard-dose pembrolizumab with 4 doses of reduced-dose ipilimumab.
Nivolumab, a monoclonal antibody targeting PD-1, does not improve OS among patients with advanced melanoma whose disease progresses after receiving ipilimumab.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Hyperthermia Plus Chemotherapy Improves Survival in Soft Tissue Sarcoma
- Survey May Help To Identify Patients With Cancer at Risk of HBV Reactivation
- Fish Consumption and Cancer
- Socioeconomic Status May Preclude Elderly Patients From Receiving Pancreatic Cancer Treatment
- Receptor Agonists With Palonosetron May Reduce Needed Dexamethasone Duration